Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2013

View Archived Issues

Astellas Pharma reflects on achievements of fiscal 2012

Genentech describes novel mTOR inhibitor, GNE-555

Researchers identify novel urine biomarkers of renal allograft rejection

In vivo efficacy and lower risk of adverse events seen in models of IPF

Erythropoietin as a biomarker of childhood asthma

Zalicus Pharmaceuticals presents in vivo data for novel calcium channel blockers

Enrollment completed in phase IIb study of Pexa-Vec for hepatocellular carcinoma

AcelRx reports on final phase III study of Sufentanil NanoTab PCA System

First stage of Oncolytics Biotech's phase II metastatic melanoma trial meets endpoint

Salix Pharmaceuticals reports data for budesonide foam in ulcerative proctitis

Empire Genomics licenses novel DNA biomarker for neuroendocrine prostate cancer

Perosphere cleared for study of PER-977 to reverse anticoagulant activity

Growth hormone as a potential biomarker of efficacy for phase I of ADX-71441

ST2 biomarker may predict organ rejection in heart transplant patients

Corgenix forms diagnostic development agreement with Lilly

uniQure and consortium to receive Eurostars grant to develop RNAi gene therapy

GlaxoSmithKline receives U.S. government grant to develop new antibiotics

Enrollment begins in NCI-sponsored trial of Prophage G-200

Nordion to divest Targeted Therapies business

Mayo Clinic and Cancer Genetics establish OncoSpire Genomics joint venture

Roche presents novel GPBAR1 agonists for diabetes

Scientists at Vereniging VU-Windesheim disclose new H4 receptor ligands

Novel autotaxin inhibitors reported by Pfizer

Allergan synthesizes novel protein-tyrosine kinase inhibitors

A team at Merck & Co. divulges novel ERK-2 inhibitors

Netherlands first to approve Vesomni